Effective atherosclerotic plaque inflammation inhibition with targeted drug delivery by hyaluronan conjugated atorvastatin nanoparticles

Abstract

Atherosclerosis is associated with inflammation in the arteries. Hyaluronan atorvastatin nanoparticle conjugate could target CD44 overexpressed in atherosclerotic plaques and significantly reduce plaque associated inflammation.

Hsa_circ_0004831 downregulation is partially responsible for atorvastatinalleviated human umbilical vein endothelial cell injuries induced by ox-LDL through targeting the miR-182-5p/CXCL12 axis

“…h, i The release of IL-6 and IL-1β in these cells. *P < 0.05, **P < 0.01, ***P < 0.001 extent of local inflammation in atherosclerotic plaques to combat AS [19]. Moreover, ATV treatment blocked the apoptotic rate and the migration ability in ox-LDL-administered HUVECs [20].…”

“…For example, ATV depleted the levels of ipoprotein remnants generated by activated brown fat, thus playing anti-atherogenic effects [ 18 ]. Besides, ATV weakened the extent of local inflammation in atherosclerotic plaques to combat AS [ 19 ]. Moreover, ATV treatment blocked the apoptotic rate and the migration ability in ox-LDL-administered HUVECs [ 20 ].…”

Nanotechnology for Targeted Therapy of Atherosclerosis

“…Huang and coworkers recently introduced HA conjugated atorvastatin nanoparticle (HA-ATV-NPs) capable of delivering atorvastatin into the inflammatory atherosclerotic plaques in ApoE knockout mice ( Hossaini Nasr et al, 2020 ). HA-ATV-NPs were constructed through chemical conjugation of ATV to HA backbone, which enabled the loading of a significant amount of ATV (35% by weight) into the NPs rendering it attractive for statin therapy.…”

Toward the Effective Bioengineering of a Pathological Tissue for Cardiovascular Disease Modeling: Old Strategies and New Frontiers for Prevention, Diagnosis, and Therapy

“…The drugs captopril, fosinopril, losartan, ramipril, and pravastatin were proved efficacious in mice, and nowadays, cardiology clinics apply them as an effective pharmacological treatment to lower hypercholesterolemia ( 144 – 147 ). Cutting-edge therapeutic strategies were also recently tested, such as microRNAs, nanoliposomes, and small interfering RNA nanoparticles to mitigate inflammation and smooth muscle cell migration ( 148 – 153 ). In addition, mouse transgenic models were useful to investigate the relationship between sex and atherogenesis, unraveling the protection from inflammation by testosterone but not from estrogen ( 154 ).…”